AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

A series of reports released today by the European Centre for Disease Prevention and Control (ECDC) show sexually transmitted ...

Pfizer (NYSE:PFE) has entered into a multi-year collaboration with Alloy Therapeutics to develop a new antibody discovery platform. Under the deal, Alloy will receive an upfront payment from Pfizer ...